[
    "led bile acid receptor 1(TGR5) agonists, such as INT-767;</p>Fatty acid synthase inhibitors, such as TVB-2640;</p>Fibroblast growth factor 19 (rhFGF19)/cytochrome P450 (CYP)7A1 inhibitors, such as NGM-282;</p>Fibroblast growth factor 21(FGF-21) ligand, such as BMS-986171, BMS-986036;</p>Fibroblast growth factor 21(FGF-21)/glucagon like peptide 1 (GLP-1) agonists, such as YH-25723;</p>Galectin-3 inhibitors, such as GR-MD-02;</p>Glucagon-like peptide 1(GLP1R) agonists, such as AC-3174, liraglutide, semaglutide;</p>G-protein coupled bile acid receptor 1(TGR5) agonists, such as RDX-009, INT-777;</p>Heat shock protein 47 (HSP47) inhibitors, such as ND-L02-s0201;</p>HMG CoA reductase inhibitors, such as atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin;</p>IL-10 agonists, such as peg-ilodecakin;</p>Ileal sodium bile acid cotransporter inhibitors, such as A-4250, volixibat potassium ethanolate hydrate (SHP-262), and GSK2330672;</p>Insulin sensitizers, such as, KBP-042, MSDC-0602K, Px-102, RG-125 (AZD4076), and VVP-100X;</p>beta Klotho (KLB)-FGF1c agonist, such as NGM-313;</p>5-Lipoxygenase inhibitors, such as tipelukast (MN-001);</p>Lipoprotein lipase inhibitors, such as CAT-2003;</p>LPL gene stimulators, such as alipogene tiparvovec;</p>Liver X receptor (LXR) modulators, such as PX-L603, PX-L493, BMS-852927, T-0901317, GW-3965, and SR-9238;</p>Lysophosphatidate-1 receptor antagonists, such as BMT-053011, UD-009. AR-479, ITMN-10534, BMS-986020, and KI-16198;</p>Lysyl oxidase homolog 2 inhibitors, such as simtuzumab;</p>Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAONAP-1) Inhibitors, such as PXS-4728A;</p>Methionine aminopeptidase-2 inhibitors, such as ZGN-839;</p>Methyl CpG binding protein 2 modulators, such as mercaptamine;</p>Mitochondrial uncouplers, such as 2,4-dinitrophenol;</p>Myelin basic protein stimulators, such as olesoxime;</p>NADPH oxidase 1/4 inhibitors, such as GKT-831;</p>Nicotinic acid receptor 1 agonists, such as ARI-3037MO;</p>NACHT LRR PYD domain protein 3 (NLRP3) inhibitors, such as KDDF-201406-03, and NBC-6;</p>Nuclear receptor modulators, such as DUR-928;</p>P2Y13 purinoceptor stimulators, such as CER-209;</p>PDE 3/4 inhibitors, such as tipelukast (MN-001);</p>PDE 5 inhibitors, such as sildenafil;</p>PDGF receptor beta modulators, such as BOT-191, BOT-509;</p>PPAR agonists, such as elafibranor (GFT-505), MBX-8025, deuterated pioglitazone R-enantiomer, pioglitazone, DRX-065, saroglitazar, and IVA-337;</p>Protease-activated receptor-2 antagonists, such as PZ-235;</p>Protein kinase modulators, such as CNX-014;</p>Rho associated protein kinase (ROCK) inhibitors, such as KD-025;</p>Sodium glucose transporter-2(SGLT2) inhibitors, such as ipragliflozin, remogliflozin etabonate, ertugliflozin, dapagliflozin, and sotagliflozin;</p>SREBP transcription factor inhibitors, such as CAT-2003 and MDV-4463;</p>Stearoyl CoA desaturase-1 inhibitors, such as aramchol;</p>Thyroid hormone receptor beta agonists, such as MGL-3196, MGL-3745, VK-2809;</p>TLR-4 antagonists, such as JKB-121;</p>Tyrosine kinase receptor modulators, such as CNX-025;</p>GPCR modulators, such as CNX-023; and</p>Nuclear hormone receptor modulators, such as Px-102.</p>In certain specific embodiments, the one or more additional therapeutic agents are selected from A-4250, AC-3174, acetylsalicylic acid, AK-20, alipogene tiparvovec, aramchol, ARI-3037M0, ASP-8232, bertilimumab, Betaine anhydrous, BI-1467335, BMS-986036, BMS-986171, BMT-053011, BOT-191, BTT-1023, CAT-2003, cenicriviroc, CER-209, CF-102, CGS21680, CNX-014, CNX-023, CNX-024, CNX-025, cobiprostone, colesevelam, dapagliflozin, deuterated pioglitazone R-enantiomer, 2,4-dinitrophenol, DRX-065, DS-102, DUR-928, EDP-305, elafibranor (GFT-505), emricasan, enalapril, ertugliflozin, evogliptin, F-351, GKT-831, GNF-5120, GR-MD-02, hydrochlorothiazide, icosapent ethyl ester, IMM-124-E, INT-767, IONIS-DGAT2Rx, ipragliflozin, Irbesarta, propagermanium, IVA-337, JKB-121, KB-GE-001, KBP-042, KD-025, M790, M780, M450, metformin, sildenafil, LC-280126, linagliptin, liraglutide, LJN-452, LMB-763, MBX-8025, MDV-4463, mercaptamine, MGL-3196, MGL-3745, MSDC-0602K, namacizumab, NC-101, ND-L02-s0201, NGM-282, NGM-313, NGM-386, NGM-395, norursodeoxycholic acid, 0-304, obeticholic acid, 25HC3S, olesoxime, PAT-505, PAT-048, peg-ilodecakin, pioglitazone, pirfenidone, PRI-724, PX20606, Px-102, PX-L603, PX-L493, PXS-4728A, PZ-235, RDX-009, remogliflozin etabonate, RG-125 (AZD4076), saroglitazar, semaglutide, simtuzumab, solithromycin, sotagliflozin, statins (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), TCM-606F, TEV-45478, tipelukast (MN-001), TLY-012, TRX-318, TVB-2640, UD-009, ursodeoxycholic acid, VBY-376, VBY-825, VK-2809, vismodegib, volixibat potassium ethanolate hydrate (SHP-626), VVP-100X, WAV-301, WNT-974, and ZGN-839.</p>EXAMPLESThe following examples are included to demonstrate specific embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques to function well in the practice of the disclosure, and thus can be considered to constitute specific modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the d"
]